Real-World Analysis of Exacerbations and Exacerbation-Related Costs Among Patients with Asthma Receiving Tezepelumab (CROSSROADS-5) (20240066) First published 28/03/2025 Last updated 04/07/2025 EU PAS number:EUPAS1000000514 Study Ongoing